A5017352283- Cardiac Arrhythmias and Treatments
- Atrial Fibrillation Management and Outcomes
- Cardiac electrophysiology and arrhythmias
- Cardiac pacing and defibrillation studies
- Cardiac Imaging and Diagnostics
- Venous Thromboembolism Diagnosis and Management
- Takotsubo Cardiomyopathy and Associated Phenomena
- ECG Monitoring and Analysis
- Cardiovascular Function and Risk Factors
- Cardiovascular Effects of Exercise
- Ion channel regulation and function
- Cardiovascular Syncope and Autonomic Disorders
- Cardiac Structural Anomalies and Repair
- Pericarditis and Cardiac Tamponade
- Cardiovascular and Diving-Related Complications
- Cardiac Valve Diseases and Treatments
- Vascular anomalies and interventions
- Pain Management and Treatment
- Heart Rate Variability and Autonomic Control
- Acute Ischemic Stroke Management
- Central Venous Catheters and Hemodialysis
- Trauma Management and Diagnosis
- COVID-19 and healthcare impacts
- Acute Myocardial Infarction Research
- Pharmaceutical studies and practices
University of Verona
2011-2025
International Renal Research Institute of Vicenza
2019-2024
Instituto Nacional de Cardiologia
2024
Azienda Ospedaliera Universitaria Integrata Verona
2010-2024
Humanitas Mater Domini
2024
Fatebenefratelli Hospital
2024
Universitair Ziekenhuis Brussel
2014-2023
Vrije Universiteit Brussel
2014-2023
Maria Cecilia Hospital
2023
Fundación Juan March
2023
Risk stratification in Brugada Syndrome (BS) remains challenging. Arrhythmic events can occur life-long and studies with long follow-ups are sparse. The aim of our study was to investigate long-term prognosis risk BS patients.A single centre consecutive cohort 400 patients included analysed. Mean age 41.1 years, 78 (19.5%) had a spontaneous type I electrocardiogram (ECG). Clinical presentation aborted sudden cardiac death (SCD) 20 (5.0%), syncope 111 (27.8%) asymptomatic 269 (67.3%)....
Abstract Background and Aims An electrical storm (ES) is a clinical emergency with paucity of established treatment options. Despite initial encouraging reports about the safety effectiveness percutaneous stellate ganglion block (PSGB), many questions remained unsettled evidence from prospective multicentre study was still lacking. For these purposes, STAR designed. Methods This observational enrolling patients suffering an ES refractory to standard 1 July 2017 30 June 2023. The primary...
A Comparison Between the First and Second Generation Balloon Background With respect to first generation Cryoballoon (CB), second (Cryoballoon Advance [CB‐A], Medtronic, Minneapolis, MN, USA) was designed with technical modifications resulting in a larger more uniform zone of freezing on balloon's surface aiming at procedural outcome improvement setting atrial fibrillation (AF) ablation. However, comparison between both technologies midterm follow‐up is missing today's literature. Methods...
The novel cryoballoon Advance (CB-A) has proven to achieve significantly lower temperatures and faster pulmonary vein isolation (PVI) times in comparison with the first-generation device. Although acutely very effective, best of our knowledge, data on mid-term clinical follow-up is lacking.The aim study was analyse freedom from recurrence atrial fibrillation (AF) a 1-year period, series consecutive patients having undergone PVI CB-A for paroxysmal AF (PAF).Forty-two [30 male (71%); mean age:...
Limited data exist on procedural and biophysical indicators of pulmonary vein (PV) isolation durability after the cryoballoon ablation atrial fibrillation (AF).The aim this study was to investigate characteristics associated with late PV reconnection (PVR) durable (PVI) cryoablation using currently available second-generation cryoballoon.Data from 435 PVs targeted in 112 consecutive patients who underwent a repeat procedure 14 ± 3 months an index AF were examined.Altogether, 111 (25.5%) 71...
The second-generation cryoballoon is effective in achieving acute pulmonary vein isolation (PVI) and favorable clinical outcome. To date, no data are available on factors affecting late PV reconnection after ablation.A total of 29 consecutive patients (25 male, 86.2%; mean age 57.8±13.8 years) underwent a repeat procedure, 11.6±4.5 months (range, 3.5-19.7 months), index ablation using the 28-mm cryoballoon. All ablations were performed 3-dimensional electroanatomical mapping system. Among...
To assess the 1 year efficacy of pulmonary vein isolation (PVI) as index procedure for persistent atrial fibrillation (PersAF) comparing conventional radiofrequency irrigated-tip catheter ablation (RFCA) using contact-force technology and second-generation cryoballoon (CB-AdvA). One hundred consecutive patients (74 male, 74%; mean age 62.4 ± 9.6 years) with drug-refractory PersAF undergoing PVI RFCA CB-AdvA were enrolled. Follow-up was based on outpatient clinic visits including...
AimsTo assess the incidence of late pulmonary vein (PV) reconnection following index PV isolation (PVI) procedure initially achieved with radiofrequency contact-force catheter ablation (CFCA) and second-generation cryoballoon (CB-AdvA).
Single 3 vs. Double 4 Strategy in CB ablation Introduction Second‐generation cryoballoon (CB‐Adv) is highly effective achieving pulmonary vein isolation (PVI) with promising mid‐term clinical outcome. However, the ideal freezing strategy still under debate. The aim of this study was to assess efficacy a single 3‐minute approach compared conventional 4‐minute plus bonus application using CB‐Adv. Methods and Results One hundred sixty patients (67% male; mean age 58.0 ± 13.3 years) underwent...
Longer observational time and adenosine challenge have proven to be able detect pulmonary vein (PV) reconnections. The aim of this study was assess incidence spontaneous adenosine-induced PV reconnection after ablation with second-generation cryoballoon (CB-Adv).Fifty consecutive patients (76% male, mean age 60.5 ± 11.9 years) having undergone isolation (PVI) using the CB-Adv were enrolled. After isolation, reconnections evaluated Achieve catheter over 30 minutes observation administration...
AimThe second-generation cryoballoon (CB-Adv) is effective in achieving pulmonary vein isolation (PVI) with encouraging results. In this study, we assessed the single-procedure outcome on a 1-year follow-up period large sample of patients having undergone PVI for drug-resistant atrial fibrillation (AF) using CB-Adv.
Abstract Aims Electrical storm (ES) is a life-threatening condition requiring rapid management. Percutaneous stellate ganglion block (PSGB) proved to be safe and effective on top of standard therapy, but no data are available about its early use. Methods results We considered all patients enrolled from 1 July 2017 30 April 2024 in the STAR registry (STellate for Arrhythmic stoRm), multicentre, international, observational, prospective registry. aimed assess effectiveness first PSGB only....
Leadless pacemakers as the Medtronic Micra AV, have improved cardiac pacing by reducing complications associated with traditional systems. However, achieving high atrioventricular synchrony (AVS) remains a challenge, especially in patients burden. This prospective study enrolled 30 to assess role of echocardiographic parameters predicting AVS postimplantation. was evaluated via 24-h Holter monitoring, median 67.9% ± 9.6%. Right atrial function, particularly tricuspidal E wave deceleration...
The purpose of this study was to analyse the efficacy and complication rates simultaneous hybrid procedure in a series patients with persistent long-standing atrial fibrillation (AF) midterm follow-up. Sixty-four consecutive (56 males, 59.7 ± 8.7 years) having undergone isolation pulmonary veins (PVs) posterior wall left atrium (LA) by means thoracoscopic ablation for symptomatic (n = 21, 33%) AF 43, 67%) were analysed. At mean follow-up 23.1 14.1 months (median 21; range 6–57), success rate...
In this double centre, retrospective study, we aimed to analyse the 1-year efficacy and safety of cryoballoon ablation (CB-A) in patients older than 75 years compared with those younger 75-years old. Fifty-three consecutive aged or drug-resistant paroxysmal AF (PAF) who underwent pulmonary vein isolation (PVI) by means second generation CB-A, were 106 <75 years. The mean age study group (>75 years) was 78.19 ± 2.7 58.97 8.5 control group. At follow-up global success rate 83.6% did not...